AI-driven cardiac ultrasound analysis” project for better heart ultrasound

Ligence starts implementing a project “AI-driven cardiac ultrasound analysis” which will increase heart ultrasound procedure accessibility, quality of procedure analysis.

Cardiovascular diseases (CVD) are the leading cause of death globally claiming 18.6M lives a year (32% of global deaths). Growing number of new CVD cases has a significant growing cost pressure impact on the EU economy.

Heart ultrasound – the two-dimensional transthoracic echocardiography (2D TTE) – is the most versatile, most widely used, and cost-effective heart imaging method. Nevertheless access to quality heart ultrasound examination and interpretation of the acquired images remains full of obstacles: examination requires a high

level of expertise, is user dependent, time consuming, prone to error and variation. Studies showed that inaccuracies can be found in a third of 2D TTE reports, an experienced cardiologist spends majority of test time on performing only manual measurements. This causes prolongation of waiting time for the procedure for the patients. Global healthcare staff shortage, ageing population and growing need for better heart state monitoring drives a need for a faster and less human-reliant 2D TTE solution.

Ligence Heart solution – AI-driven application which automatically evaluates heart ultrasound images. Ligence Heart solution will be improved during the project to meet clinicians needs better. Ligence is remodelling the quality, difficulty, and length of echocardiography with an AI-driven tool to automate the whole analysis of heart ultrasound images and standartise echocardiography reporting and seeks to become 2D TTE solution seamlessly integrating with the existing infrastructure in hospitals.

Automated 2D TTE analysis will result in dramatically increased accessibility and analysis quality, earlier diagnosis, and better patient risk stratification, monitoring, and patient management.

Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

Share the Post:

Related Posts

In a bold stride towards innovation, we are excited to announce the latest enhancements to our flagship product, the Ligence Heart web app software. Through meticulous development and optimization, we've
In a bold stride towards innovation, we are excited to announce the latest enhancements to our flagship product, the Ligence Heart web app software. Through meticulous development and optimization, we've